Cargando…
Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation
Autor principal: | Deeg, H. Joachim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905709/ https://www.ncbi.nlm.nih.gov/pubmed/34607346 http://dx.doi.org/10.1182/bloodadvances.2021004799 |
Ejemplares similares
-
Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation
por: Tey, Siok-Keen, et al.
Publicado: (2022) -
Should Requirements for Nurses Be Relaxed During Health Emergencies?
por: Gardenier, Donald, et al.
Publicado: (2021) -
Counterpoint: Flexibilization of Fasting for Laboratory Determination
of the Lipid Profile in Brazil: Science or Convenience?
por: Izar, Maria Cristina de Oliveira
Publicado: (2018) -
Research methods in international business: The challenge of complexity
por: Eden, Lorraine, et al.
Publicado: (2020) -
Why the world economy needs, but will not get, more globalization in the post-COVID-19 decade
por: Ciravegna, Luciano, et al.
Publicado: (2021)